WPC
LGND icon

Waters Parkerson & Co’s Ligand Pharmaceuticals LGND Stock Holding History

Waters Parkerson & Co’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,040
Closed -$304K – 186
2024
Q3 		$304K Buy
+3,040
New +$306K 0.02% 159

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Waters Parkerson & Co's LGND Position: Q4 2024 in Review

Waters Parkerson & Co sold out of Ligand Pharmaceuticals (LGND) in Q4 2024, closing a stake of 3,040 shares — an estimated $304K sold.

Waters Parkerson & Co first reported a position in LGND in Q3 2024 and held it in 1 quarter. The position peaked at $304K in Q3 2024. 258 funds tracked by Wall St. Rank hold LGND as of Q4 2024.

  • Waters Parkerson & Co reported no remaining Ligand Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Waters Parkerson & Co sold 3,040 Ligand Pharmaceuticals shares in Q4 2024, an estimated $304K.
  • Waters Parkerson & Co first reported a position in Ligand Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Waters Parkerson & Co's Ligand Pharmaceuticals position peaked at $304K in Q3 2024.
  • 258 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2024.

Based on Waters Parkerson & Co's 13F filing for Q4 2024, filed 14 Feb 2025.